🇺🇸 Metoprolol XL in United States

256 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Fatigue — 34 reports (13.28%)
  2. Myocardial Infarction — 33 reports (12.89%)
  3. Dizziness — 26 reports (10.16%)
  4. Asthenia — 25 reports (9.77%)
  5. Dyspnoea — 25 reports (9.77%)
  6. Cardiac Failure Congestive — 23 reports (8.98%)
  7. Diarrhoea — 23 reports (8.98%)
  8. Drug Ineffective — 23 reports (8.98%)
  9. Nausea — 23 reports (8.98%)
  10. Headache — 21 reports (8.2%)

Source database →

Metoprolol XL in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Metoprolol XL approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Metoprolol XL in United States?

Emory University is the originator. The local marketing authorisation holder may differ — check the official source linked above.